Tiziana Life Sciences (TLSA) Common Equity (2017 - 2025)

Tiziana Life Sciences (TLSA) has reported Common Equity for 9 consecutive years, with $52000.0 the latest figure, recorded in Q4 2025.

• Quarterly Common Equity fell 98.68% year-over-year to $52000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $52000.0 (down 98.68% YoY) and the FY2025 annual result came in at $52000.0, up 100.44% from the prior year.
• Common Equity advanced to $52000.0 in Q4 2025 per TLSA's latest filing, from -$5.6 million in the prior quarter.
• Over the last five years, Common Equity for TLSA reached as high as $41.3 million in Q4 2021 and fell as low as -$17.0 million in Q2 2021.
• A 5-year average of $3.0 million and a median of -$2.2 million in 2022 frame the typical range for Common Equity.
• The largest YoY upside for Common Equity was 253.64% in 2021 against a maximum downside of 248.34% in 2021.
• Year by year, Common Equity stood at $41.3 million in 2021, then tumbled by 52.59% to $19.6 million in 2022, then sank by 71.71% to $5.5 million in 2023, then dropped by 28.9% to $3.9 million in 2024, then plunged by 98.68% to $52000.0 in 2025.
• According to Business Quant data, Common Equity over the past three periods registered $52000.0, -$5.6 million, and $3.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.